Skip to main content
TipRanks
Go Ultimate75% OFF

Senores Pharmaceuticals Ltd. (SENORES) AI Stock Analysis

1 Followers
IN:SENORES

Senores Pharmaceuticals Ltd.

(NSE:SENORES)

Select Model
Rating:63Neutral
Price Target:INR 1,213.00â–²(11.07% Upside)
Action:reiterated
Date:09/13/26

Financial performance drives the score via strong revenue growth and margin gains, supported by positive technical momentum; high valuation from stretched P/E tempers the outlook.

Positive Factors
Revenue Scale-UpThe sharp FY2026 revenue increase indicates substantial expansion in business scale and market activity. If the enlarged revenue base is sustained, it can support operating leverage, broader commercial reach, and stronger capacity to fund future growth initiatives.
Negative Factors
Persistent Negative Free Cash FlowRepeatedly negative free cash flow indicates that reported growth and profitability have not translated into cash available after investment or operating needs. Continued cash consumption could require external funding and may limit the company’s flexibility to pursue expansion.

Senores Pharmaceuticals Ltd. (SENORES) vs. iShares MSCI India ETF (INDA)

-20%0%20%40%60%80%100%IN:SENORES+33.51%INDA-5.96%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 50.11B
Dividend Yield
―
Average Volume (3M)
23.86K
Price to Earnings (P/E)
35.7
Beta (1Y)
0.73
Revenue Growth
39.71%
EPS Growth
53.21%
Country
India
Employees
368
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - General

Senores Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Established in 2017 and headquartered in Ahmedabad, India, Senores Pharmaceuticals Ltd. is actively involved in the development, manufacturing, and global commercialization of pharmaceutical and related products. Its extensive portfolio reaches marke...

Senores Pharmaceuticals Ltd. Financial Statement Overview

Summary

Exceptional revenue growth over 150% with net margin expansion to 18%, solid balance sheet growth and leverage at 0.37, offset by deeply negative free cash flow from heavy capex.

Income Statement

85Very Positive

Balance Sheet

70Positive

Cash Flow

40Negative
Financial statement breakdown
BreakdownTTMMar 2025Mar 2025
Income Statement
Total Revenue2.52B3.83B6.33B
Gross Profit1.29B14.11M3.81B
EBITDA849.50M1.08B2.15B
Net Income502.10M6.85M1.15B
Balance Sheet
Total Assets12.88B145.66M16.04B
Cash, Cash Equivalents and Short-Term Investments3.60B3.85B3.32B
Total Debt2.41B3.15B3.42B
Total Liabilities4.54B50.70M6.39B
Stockholders Equity8.14B7.86B9.34B
Cash Flow
Free Cash Flow-2.27B-2.03B-2.03B
Operating Cash Flow-280.86M-459.20M620.50M
Investing Cash Flow-3.34B-4.29B-1.21B
Financing Cash Flow4.39B5.73B-13.30M

Senores Pharmaceuticals Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price1092.15

Price Trends

50DMA1307.40Negative
100DMA1359.13Negative
200DMA1133.33Positive

Market Momentum

MACD-42.90Negative
RSI39.49Neutral
STOCH37.11Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SENORES, the sentiment is Negative. The current price of 1092.15 is below the 20-day moving average (MA) of 1195.09, below the 50-day MA of 1307.40, and below the 200-day MA of 1133.33, indicating a neutral trend. The MACD of -42.90 indicates Negative momentum. The RSI at 39.49 is Neutral, neither overbought nor oversold. The STOCH value of 37.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SENORES.

Senores Pharmaceuticals Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:SENORES against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:ABBOTINDIAIN:ABBOTINDIA69NeutralINR 549.48B32.74―2.03%7.21%9.54%
IN:MARKSANSIN:MARKSANS69NeutralINR 138.58B23.83―0.30%24.20%59.18%
IN:SMSPHARMAIN:SMSPHARMA63NeutralINR 44.72B37.66―0.08%12.96%32.16%
IN:SENORESIN:SENORES63NeutralINR 50.30B35.72――39.71%53.21%
IN:KOPRANIN:KOPRAN60NeutralINR 12.83B32.67―1.13%34.11%123.11%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

0%50%100%IN:SENORESIN:ABBOTINDIAIN:KOPRANIN:MARKSANSIN:SANOFICONRIN:SMSPHARMADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:SENORES and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:SENORESSenores Pharmaceuticals Ltd.1092.15263.5031.80%
IN:ABBOTINDIAAbbott India Limited25490.90-3382.70-11.72%
IN:KOPRANKopran Limited265.50133.74101.50%
IN:MARKSANSMarksans Pharma Limited295.35102.9353.49%
IN:SANOFICONRSanofi Consumer Healthcare India Limited3528.50-1131.97-24.29%
IN:SMSPHARMASMS Pharmaceuticals Limited477.50194.0468.46%

Senores Pharmaceuticals Ltd. Corporate Events

Senores Pharmaceuticals Moves to Extend Top Leadership Terms

Oct 13, 2026

Senores Pharmaceuticals’ Board has approved the re-appointment of Managing Director Swapnil Jatinbhai Shah for a three-year term starting October 15, 2026, subject to shareholder approval via postal ballot. The decision, made on the recommendation of...

Senores Pharmaceuticals Reappoints Key Directors, Emphasizing Leadership Continuity

Oct 13, 2026

Senores Pharmaceuticals Ltd. has reaffirmed its leadership structure by approving the re-appointment of Managing Director Swapnil Jatinbhai Shah for a further three-year term starting October 15, 2026, subject to shareholder approval via a postal bal...

Senores Pharmaceuticals Reappoints Key Directors to Strengthen Leadership Continuity

Oct 13, 2026

As part of its latest corporate governance actions, Senores Pharmaceuticals has approved the re-appointment of Managing Director Swapnil Jatinbhai Shah for a three-year term starting October 15, 2026, subject to shareholder approval via a postal ball...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 13, 2026